title: Commentary on androgen deficiency in women and the FDA advisory board's recent decision to request more safety data.
abstract: Editor's note: The FDA's decision regarding Intrinsa has potential widespread implications for the medical treatment of female sexual dysfunction (FSD). Dr Andre Guay is a world-renowned authority on the topic of female sexuality and FSD. Accompanying Dr Spark's perspective in issue 2, this perspective will shed important light on the topic and offer insight into the past, present and future of FSD.
authors.affiliation: Center for Sexual Function, Lahey Clinic, Peabody, MA 1960, USA. Andre.T.Guay@lahey.org
authors.forename: A
authors.initials: A
authors.lastname: Guay
mesh_terms: D000728:Androgens / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency*; D017277:Drug Approval; D005260:Female; D006801:Humans; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000728:Androgens; D013739:Testosterone